Palatin Technologies

27% growth in prescriptions dispensed over prior quarter; 147% growth over comparable quarter in 2022. 5 consecutive quarters of double-digit growth. Click here to learn more ›

Resources

Informative Resources

Melanocortin 1 Receptor (MC1R) Agonist PL8177 Protects Against Podocyte Loss in a Streptozotocin-Induced Rat Model of Diabetic Nephropathy

Efficacy of the Melanocortin Receptor Agonist PL8177 as a Potential Therapy for Gastrointestinal Inflammatory Diseases

Effectiveness of PL9643 in Treating the Signs and Symptoms of Moderate to Severe Dry Eye Disease: Results From 2 Independent Clinical Trials

Melanocortin Receptor Agonist PL9588 Reduces Intraocular Pressure in Normotensive Rabbits

Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder

Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder

Melanocortin Agonist PL9643 Significantly Improves Ocular Signs and Symptoms of Moderate to Severe Dry Eye Disease, Including Tear Film Break Up Time

Efficacy and Impact of the Melanocortin Receptor Agonists PL8177 and PL9654 in an STZ-Rat Model of Diabetic Retinopathy

Eyecelerator at ASCRS

KOL Webinar on Dry Eye Disease